Blurbs

Halozyme (HALO) Gets a Buy from SVB Securities

In a report released on August 9, Research Report). The company’s shares closed yesterday at $44.10.

Risinger covers the Healthcare sector, focusing on stocks such as Pfizer, Sanofi, and Eli Lilly & Co. According to TipRanks, Risinger has an average return of 3.2% and a 47.62% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Halozyme with a $54.00 average price target, implying a 22.45% upside from current levels. In a report released yesterday, JMP Securities also reiterated a Buy rating on the stock with a $60.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

HALO market cap is currently $5.98B and has a P/E ratio of 17.16.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Read More on HALO:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos